Mission Biocapital

Mission BioCapital, founded in 2009, is a venture capital firm that focuses on early-stage investments in life sciences companies. With offices in Cambridge, Massachusetts, and San Francisco, California, the firm supports startups from the idea phase through to key development milestones. Mission BioCapital emphasizes collaboration and innovation, providing capital and strategic support to help scientific solutions reach the clinic faster and more efficiently. The firm recently announced raising $275 million for its fifth fund, Mission BioCapital V, which is aimed at funding transformative startups in therapeutics, diagnostics, medical devices, laboratory tools, and drug delivery. This fund also emphasizes company creation, working with academic researchers and entrepreneurs to launch startups based on novel technologies. Notable portfolio companies include Caribou Biosciences, Effector Therapeutics, and Alector, with several successful exits and IPOs. Mission BioCapital has also co-founded companies like ARase Therapeutics, Arclight Therapeutics LLC, Jupiter Bioventures, and Telo Therapeutics, demonstrating its deep involvement in nurturing groundbreaking life science ventures. The team at Mission BioCapital includes experienced professionals like Dr. Michael D. Taylor, who has a significant background in drug development at Pfizer and startups like Deciphera Pharmaceuticals. Co-Managing Partner Steve Tregay also brings extensive experience from his tenure at FORMA Therapeutics and the Novartis Venture Fund.